MedTrace Logo

Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

NCT00002844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2018-10-25

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with chronic lymphocytic leukemia.

Conditions

Interventions

DRUG

Cyclophosphamide

Daily intravenous infusions of cyclophosphamide for two days,

PROCEDURE

Allogeneic Bone Marrow Transplantation

After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.

PROCEDURE

Autologous Bone Marrow Transplantation

After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.

RADIATION

Total Body Irradiation (TBI)

Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Richard E. Champlin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-03-05
Primary Completion
2002-06-05
Completion
2002-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002844 on ClinicalTrials.gov